Importer of Controlled Substances; Notice of Application GE Healthcare, 36594-36595 [2013-14456]

Download as PDF 36594 Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices Drug Schedule mstockstill on DSK4VPTVN1PROD with NOTICES Hydromorphone (9150) ............................................................................................................................................................................... Diphenoxylate (9170) .................................................................................................................................................................................. Ecgonine (9180) .......................................................................................................................................................................................... Ethylmorphine (9190) .................................................................................................................................................................................. Hydrocodone (9193) .................................................................................................................................................................................... Levomethorphan (9210) .............................................................................................................................................................................. Levorphanol (9220) ..................................................................................................................................................................................... Isomethadone (9226) .................................................................................................................................................................................. Meperidine (9230) ....................................................................................................................................................................................... Meperidine intermediate-B (9233) ............................................................................................................................................................... Metazocine (9240) ....................................................................................................................................................................................... Methadone (9250) ....................................................................................................................................................................................... Methadone intermediate (9254) .................................................................................................................................................................. Metopon (9260) ........................................................................................................................................................................................... Dextropropoxyphene, bulk (non-dosage forms) (9273) .............................................................................................................................. Morphine (9300) .......................................................................................................................................................................................... Thebaine (9333) .......................................................................................................................................................................................... Dihydroetorphine (9334) .............................................................................................................................................................................. Levo-alphacetylmethadol (9648) ................................................................................................................................................................. Oxymorphone (9652) ................................................................................................................................................................................... Noroxymorphone (9668) .............................................................................................................................................................................. Phenazocine (9715) .................................................................................................................................................................................... Piminodine (9730) ....................................................................................................................................................................................... Racemethorphan (9732) .............................................................................................................................................................................. Racemorphan (9733) ................................................................................................................................................................................... Alfentanil (9737) .......................................................................................................................................................................................... Remifentanil (9739) ..................................................................................................................................................................................... Sufentanil (9740) ......................................................................................................................................................................................... Carfentanil (9743) ........................................................................................................................................................................................ Tapentadol (9780) ....................................................................................................................................................................................... Bezitramide (9800) ...................................................................................................................................................................................... Fentanyl (9801) ........................................................................................................................................................................................... The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I and II, which fall under the authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 18, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of VerDate Mar<15>2010 16:52 Jun 17, 2013 Jkt 229001 any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: June 7, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–14446 Filed 6–17–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application GE Healthcare Pursuant to Title 21, Code of Federal Regulations 1301.34(a), this is notice that on April 29, 2013, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Cocaine PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II (9041), a basic class of controlled substance listed in schedule II. The company plans to import small quantities of ioflupane, in the form of three separate analogues of Cocaine, to validate production and quality control systems, for a reference standard, and for producing material for a future investigational new drug (IND) submission. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance listed in schedules I and II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43, and in such form as prescribed by 21 CFR § 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 18, 2013. This procedure is to be conducted simultaneously with, and independent E:\FR\FM\18JNN1.SGM 18JNN1 Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic classes of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR § 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: June 7, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–14456 Filed 6–17–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Registration, National Center for Natural Products Research-NIDA; Correction In Federal Register (FR DOC) 2013– 09325 on page 23597, in the issue of Friday, April 19, 2013, make the following correction: On page 23597, in the first column, in the table, the last cells, ‘‘II’’ should read ‘‘I’’. Dated: June 7, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–14442 Filed 6–17–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs mstockstill on DSK4VPTVN1PROD with NOTICES [OMB Number 1121–0277] Agency Information Collection Activities; Proposed Collection; Comments Requested; Revisions of Currently Approved Collection and Extension of Currently Approved Collection: OJJDP National Training and Technical Assistance Center (NTTAC) Evaluation Feedback Form Package ACTION: Overview of This Information Collection 30-Day Notice. The Department of Justice, Office of Justice Programs will be submitting the VerDate Mar<15>2010 16:52 Jun 17, 2013 Jkt 229001 following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the Federal Register Volume 78, Number 52, page 16710 on March 18, 2013, allowing for a 60-day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until July 18, 2013. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officers, Washington, DC 20503. Additionally comments may be submitted to OMB via facsimile to (202) 395–7285. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency/component, including whether the information will have practical utility; (2) Evaluate the accuracy of the agencies/components estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. (1) Type of Information Collection: Extension of a currently approved collection. (2) The Title of the Form/Collection: OJJDP NTTAC Evaluation Feedback Form Package. (3) The Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Office of Juvenile Justice and PO 00000 Frm 00090 Fmt 4703 Sfmt 9990 36595 Delinquency Prevention, Office of Justice Programs, Department of Justice. (4) Affected public who will be asked or required to respond, as well as a brief abstract. Primary: State, Local, or Tribal. Other: Federal Government, Individuals or households; Not-for-profit institutions; Businesses or other forprofit. The Office for Juvenile Justice and Delinquency Prevention National Training and Technical Assistance Center (NTTAC) Evaluation Feedback Form Package is designed to collect inperson and online data necessary to continuously assess the outcomes of the assistance provided for both monitoring and accountability purposes and for continuously assessing and meeting the needs of the field. OJJDP NTTAC will send these forms to technical assistance (TA) recipients; conference attendees; training and TA providers; online meeting participants; in-person meeting participants; and focus group participants to capture important feedback on the recipients’ satisfaction with the quality, efficiency, referrals, information and resources provided and assess the recipients’ additional training and TA needs. The data will then be used to advise NTTAC on ways to improve the support provided to its users; the juvenile justice field at-large; and ultimately improve services and outcomes for youth. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that 5140 respondents will complete forms and the response time will range from .03 hours to 1.5 hours. (6) An estimate of the total public burden (in hours) associated with the collection: There are an estimated 470.83 total annual burden hours associated with this collection. If additional information is required contact: Jerri Murray, Department Clearance Officer, U.S. Department of Justice, Planning and Policy Staff, Justice Management Division, 145 N Street NE., Room 1407B, Washington, DC 20530. Dated: June 12, 2013. Jerri Murray, Department Deputy Clearance Officer, United States Department of Justice. [FR Doc. 2013–14355 Filed 6–17–13; 8:45 am] BILLING CODE 4410–18–P E:\FR\FM\18JNN1.SGM 18JNN1

Agencies

[Federal Register Volume 78, Number 117 (Tuesday, June 18, 2013)]
[Notices]
[Pages 36594-36595]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14456]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application GE 
Healthcare

    Pursuant to Title 21, Code of Federal Regulations 1301.34(a), this 
is notice that on April 29, 2013, GE Healthcare, 3350 North Ridge 
Avenue, Arlington Heights, Illinois 60004-1412, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as an importer of Cocaine (9041), a basic class of controlled substance 
listed in schedule II.
    The company plans to import small quantities of ioflupane, in the 
form of three separate analogues of Cocaine, to validate production and 
quality control systems, for a reference standard, and for producing 
material for a future investigational new drug (IND) submission.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance listed in schedules I and II, which falls under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in 
the circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR Sec.  1301.43, and in such form as prescribed by 21 
CFR Sec.  1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 18, 2013.
    This procedure is to be conducted simultaneously with, and 
independent

[[Page 36595]]

of, the procedures described in 21 CFR Sec.  1301.34(b), (c), (d), (e), 
and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, 40 FR 43745-46, all applicants for 
registration to import a basic classes of any controlled substances in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
Sec.  1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-14456 Filed 6-17-13; 8:45 am]
BILLING CODE 4410-09-P